Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 298Thoracic 191Breast 106Head & Neck 70Gynecologic 62Lymphoid 45Other hematologic neoplasm 39CNS 34Genitourinary 27Sarcoma 25Other solid neoplasm 18Tumor-Agnostic 14Dermatologic 10Plasma cell 8Myeloid 7Classical hematology 6Other 3Endocrine 3NET 2Other neoplasm 1

Conditions

Neuroendocrine Tumors 1Carcinoma, Neuroendocrine 1Advanced Pancreatic Neuroendocrine Tumor 1

Interventions

lutetium Lu 177 dotatate 32Everolimus 19Magnetic Resonance Spectroscopy 14gallium Ga 68 dotatate 12Temozolomide 12Nivolumab 11Capecitabine 10pembrolizumab 9lanreotide 9cabozantinib 8Positron Emission Tomography Computed Tomography 8177Lu-octreotide, DOTA(0)-Tyr(3)- 8Ga(III)-DOTATOC 73-Iodobenzylguanidine 7Somatostatin 6Octreotide 6Lutetium-177 6Carboplatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5surufatinib 5lenvatinib 5Ipilimumab 5Fluorodeoxyglucose F18 5pasireotide 4copper dotatate CU-64 4avelumab 4Single Photon Emission Computed Tomography Computed Tomography 4Positron-Emission Tomography 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Drug Therapy × NET × Clear all
NCT04464122 2025-04-03

REBORN

University of Roma La Sapienza

Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06246630 2024-05-16

In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor

Ruijin Hospital

Phase NA Recruiting
20 enrolled
EndocrineGastrointestinalNET

Advanced Pancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡